# OnCo record bp2202 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bp2202/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bp2202" ;
  schema:name "BP2202"@en ;
  schema:description "BP2202 is an experimental iPS cell-derived CAR-iNKT cell therapy from BrightPath Biotherapeutics, in phase 1 trials for relapsed or refractory multiple myeloma."@en ;
  schema:url <https://onco.cc/drugs/bp2202/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.brightpathbio.com/pipeline/bp2202.html>, <https://www.brightpathbio.com/pipeline/bp2202.html>, <https://clinicaltrials.gov/api/v2/studies/NCT07667868>, <https://clinicaltrials.gov/search?intr=BP2202> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "iPS cell-derived CAR-iNKT cell therapy (allogeneic)" ;
  onco:cancers <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:targets <https://onco.cc/targets/bcma/> ;
  onco:companies <https://onco.cc/companies/brightpath-biotherapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07667868/> .